Yes, when I initially read about the proposed Rosacea trial I was sceptical because I was picturing more of what you describe, mild and with a strong genetic underlying predisposition, however papulopustular is quite a nasty errupion with strong inflamation and a bacterial component, 2 things that hypothetically bot should be able to address and hence reduce the suffering for what is an acute phase of a chronic conditon. We will not be curing rosacea broadly as such but thats ok.
Ann: BTX 1702 Rosacea Study Approval, page-42
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $742.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 43.0¢ | 40.5¢ | $3.179M | 7.658M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 83000 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 367540 | 8 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |